The Pharmacy Times® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.
April 25th 2024
A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung Cancer
1.5 Credits / Lung Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
May 21st 2021In a trial of amivantamab-vmjw, investigators found an overall response rate of 40% among patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 20 insertion mutations.
Read More
HOPA 2021: New Therapies on the Horizon for Advanced NSCLC
April 13th 2021A session at the Hematology/Oncology Pharmacy Association Virtual Annual Conference provided an overview of how treatment options are changing with potential new therapies in development for patients with non-small cell lung cancer.
Read More
Integrating Palliative Care Early in Cancer Diagnosis Improves Quality of Life, May Improve Outcomes
April 8th 2021In patients who received early palliative care, researchers noted a lower percentage of patients with depression, improved quality of life, and, significantly, longer survival.
Read More
FDA Approves Libtayo as Monotherapy for Advanced Non-Small Cell Lung Cancer
February 23rd 2021This is the third approval for Libtayo, following approvals as the first immunotherapy for patients with advanced basal cell carcinoma and as the first systemic treatment for advanced cutaneous squamous cell carcinoma.
Read More
Study: High Rate of Smoking Reduction, Cessation in Patients With Lung Cancer Following Study Entry
February 17th 2021A recent comprehensive, prospective study of smoking habits among patients with non-small cell lung cancer demonstrated a high rate of smoking reduction and cessation following entry into the phase 3 early-stage trial.
Read More
FDA Approves Treatment for Chemotherapy-Induced Bone Marrow Suppression in Small Cell Lung Cancer
February 15th 2021The FDA has approved trilaciclib (Cosela) to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.
Read More
Biologics License Application for Bevacizumab Biosimilar BAT1706
January 29th 2021If approved, the biosimilar will be indicated for use in metastatic colorectal cancer, nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer.
Read More
FDA Grants Breakthrough Designation to Tiragolumab Plus Atezolizumab for NSCLC
January 7th 2021The FDA has granted a breakthrough therapy designation to tiragolumab for use in combination with atezolizumab (Tecentriq) in the frontline treatment of patients with metastatic non­–small cell lung cancer.
Read More
FDA Approves FoundationOne Liquid CDx for Breast, Ovarian, Lung Cancer Indications
October 28th 2020FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
Read More